Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy ready for re-inspection

This article was originally published in The Gold Sheet

Executive Summary

Ranbaxy has asked FDA to re-inspect its Paonta Sahib and Dewas manufacturing sites in India, CEO Atul Sobti told PharmAsia News. The company has provided the agency a report explaining how it corrected problems FDA noted in previous inspections, and which led the agency in September to suspend imports of more than 30 products. A favorable re-inspection could enable Ranbaxy, now owned by Japanese drug maker Daiichi Sankyo, to resume U.S. exports (see "The Gold Sheet," March 2009, p. 11 and "The Gold Sheet," August 2008, p. 6)

You may also be interested in...



Time Waits for No Lab, Ranbaxy Learns

Time waits for no lab learn Ranbaxy and new owner Daiichi Sankyo as stock sinks after FDA sanctions firm for holding stability testing samples in refrigerators until its overworked lab could get around to testing them. Lab was backdating same-day testing of 30-, 60- and 90-day samples, FDA said as it slapped Ranbaxy with application integrity letter.

Ranbaxy Internal Audit Disclosure Highlights FDA Policy Exceptions

FDA went to court for a look at Ranbaxy’s internal audits despite its longstanding policy against routinely reviewing such documents. However, a 1996 revision made exceptions for cases like Ranbaxy’s, in which the agency is pursuing allegations of fraud.

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel